 Ilango Balakrishnan
Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 8 | 2025 | 395 | 1.680 |
Why?
| | Brain Neoplasms | 7 | 2025 | 1238 | 0.980 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.960 |
Why?
| | Medulloblastoma | 6 | 2022 | 193 | 0.680 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 50 | 0.660 |
Why?
| | Cerebellar Neoplasms | 5 | 2022 | 152 | 0.600 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1430 | 0.580 |
Why?
| | Cell Line, Tumor | 15 | 2025 | 3412 | 0.560 |
Why?
| | Bone Marrow Cells | 2 | 2014 | 316 | 0.470 |
Why?
| | MicroRNAs | 3 | 2014 | 692 | 0.380 |
Why?
| | Rhabdoid Tumor | 2 | 2025 | 99 | 0.380 |
Why?
| | Genome, Human | 2 | 2014 | 425 | 0.380 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2025 | 1396 | 0.370 |
Why?
| | Cell Cycle Proteins | 5 | 2022 | 617 | 0.360 |
Why?
| | Aging | 1 | 2020 | 1864 | 0.330 |
Why?
| | Cell Proliferation | 8 | 2025 | 2475 | 0.310 |
Why?
| | Apoptosis | 8 | 2025 | 2553 | 0.270 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2025 | 872 | 0.260 |
Why?
| | Neoplastic Stem Cells | 2 | 2025 | 399 | 0.250 |
Why?
| | Nuclear Proteins | 3 | 2017 | 712 | 0.250 |
Why?
| | Sirtuin 2 | 1 | 2025 | 24 | 0.230 |
Why?
| | SMARCB1 Protein | 1 | 2025 | 31 | 0.230 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2025 | 27 | 0.230 |
Why?
| | Histones | 2 | 2020 | 636 | 0.230 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.220 |
Why?
| | Proto-Oncogene Proteins | 3 | 2022 | 648 | 0.220 |
Why?
| | Macrophage Activation | 1 | 2025 | 201 | 0.220 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2020 | 434 | 0.210 |
Why?
| | Pyrazoles | 4 | 2022 | 423 | 0.210 |
Why?
| | Phagocytosis | 1 | 2025 | 380 | 0.210 |
Why?
| | Epigenomics | 2 | 2020 | 115 | 0.200 |
Why?
| | Genes, myc | 2 | 2020 | 48 | 0.200 |
Why?
| | Stromal Cells | 2 | 2014 | 112 | 0.190 |
Why?
| | Mutation | 2 | 2025 | 3958 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 65 | 0.180 |
Why?
| | Antineoplastic Agents | 3 | 2022 | 2129 | 0.180 |
Why?
| | Pyrimidinones | 2 | 2020 | 113 | 0.180 |
Why?
| | Radiation Tolerance | 1 | 2022 | 96 | 0.180 |
Why?
| | Mice | 8 | 2025 | 17787 | 0.170 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 40 | 0.160 |
Why?
| | Brain Stem Neoplasms | 1 | 2020 | 83 | 0.160 |
Why?
| | Down-Regulation | 2 | 2014 | 657 | 0.160 |
Why?
| | Astrocytoma | 1 | 2020 | 128 | 0.160 |
Why?
| | Chromatin | 2 | 2020 | 519 | 0.160 |
Why?
| | Deoxycytidine | 1 | 2020 | 179 | 0.150 |
Why?
| | Lysine | 1 | 2020 | 294 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 528 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1079 | 0.140 |
Why?
| | Macrophages | 1 | 2025 | 1547 | 0.140 |
Why?
| | Argonaute Proteins | 2 | 2014 | 27 | 0.130 |
Why?
| | RNA, Messenger | 3 | 2014 | 2833 | 0.130 |
Why?
| | Cell Differentiation | 2 | 2025 | 1991 | 0.130 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 30 | 0.130 |
Why?
| | Animals | 9 | 2025 | 36940 | 0.130 |
Why?
| | Pteridines | 1 | 2016 | 20 | 0.130 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2016 | 43 | 0.130 |
Why?
| | Immunophenotyping | 1 | 2017 | 318 | 0.130 |
Why?
| | Ependymoma | 1 | 2017 | 165 | 0.120 |
Why?
| | Humans | 19 | 2025 | 137585 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 327 | 0.120 |
Why?
| | Serrate-Jagged Proteins | 1 | 2014 | 27 | 0.110 |
Why?
| | Jagged-1 Protein | 1 | 2014 | 23 | 0.110 |
Why?
| | Wnt-5a Protein | 1 | 2014 | 23 | 0.110 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2014 | 56 | 0.110 |
Why?
| | Immunoprecipitation | 1 | 2014 | 155 | 0.110 |
Why?
| | NF-kappa B | 1 | 2017 | 691 | 0.100 |
Why?
| | Cellular Microenvironment | 1 | 2014 | 84 | 0.100 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2014 | 539 | 0.100 |
Why?
| | Wnt Proteins | 1 | 2014 | 133 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2014 | 139 | 0.100 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 218 | 0.100 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2014 | 382 | 0.090 |
Why?
| | Biomarkers, Tumor | 2 | 2016 | 1276 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2014 | 545 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 411 | 0.090 |
Why?
| | Cell Line | 2 | 2014 | 2847 | 0.090 |
Why?
| | Cerebellum | 1 | 2012 | 224 | 0.090 |
Why?
| | Chemokine CXCL12 | 1 | 2010 | 81 | 0.090 |
Why?
| | Base Sequence | 1 | 2014 | 2181 | 0.080 |
Why?
| | Child, Preschool | 3 | 2020 | 11074 | 0.080 |
Why?
| | Molecular Sequence Data | 1 | 2014 | 2900 | 0.080 |
Why?
| | Child | 4 | 2025 | 21935 | 0.070 |
Why?
| | Female | 4 | 2025 | 73304 | 0.070 |
Why?
| | Endothelial Cells | 1 | 2014 | 785 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2014 | 1164 | 0.070 |
Why?
| | Transcription Factors | 1 | 2014 | 1719 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2025 | 38 | 0.060 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 660 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2016 | 767 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2025 | 217 | 0.050 |
Why?
| | Cell Survival | 2 | 2016 | 1120 | 0.050 |
Why?
| | DNA Repair | 1 | 2024 | 231 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 44 | 0.050 |
Why?
| | Radiation, Ionizing | 1 | 2022 | 80 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2010 | 2607 | 0.040 |
Why?
| | 3' Untranslated Regions | 2 | 2012 | 145 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 233 | 0.040 |
Why?
| | Cell Cycle | 2 | 2014 | 601 | 0.040 |
Why?
| | RNA Polymerase II | 1 | 2024 | 324 | 0.040 |
Why?
| | Teratoma | 1 | 2022 | 114 | 0.040 |
Why?
| | Quinazolines | 1 | 2022 | 251 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 227 | 0.040 |
Why?
| | Piperazines | 1 | 2022 | 350 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 622 | 0.040 |
Why?
| | Sulfonamides | 1 | 2022 | 513 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2024 | 1457 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 17 | 0.030 |
Why?
| | Prognosis | 2 | 2016 | 4030 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 840 | 0.030 |
Why?
| | Urea | 1 | 2016 | 81 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 117 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 378 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 686 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2167 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 320 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 889 | 0.030 |
Why?
| | Azepines | 1 | 2014 | 90 | 0.030 |
Why?
| | DNA Damage | 1 | 2016 | 420 | 0.030 |
Why?
| | Male | 1 | 2020 | 67762 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 843 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 812 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 346 | 0.030 |
Why?
| | Cathepsin B | 1 | 2012 | 14 | 0.030 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.030 |
Why?
| | Triazoles | 1 | 2014 | 147 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1250 | 0.020 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2012 | 42 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 698 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2014 | 955 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 976 | 0.020 |
Why?
| | Colorado | 1 | 2022 | 4565 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1226 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 510 | 0.020 |
Why?
| | Neural Stem Cells | 1 | 2012 | 156 | 0.020 |
Why?
| | CD146 Antigen | 1 | 2010 | 42 | 0.020 |
Why?
| | Pyrimidines | 1 | 2014 | 470 | 0.020 |
Why?
| | Chemotaxis | 1 | 2010 | 131 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 318 | 0.020 |
Why?
| | Hematopoiesis | 1 | 2010 | 192 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1972 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2012 | 427 | 0.020 |
Why?
| | Ligands | 1 | 2010 | 664 | 0.020 |
Why?
| | Genomics | 1 | 2014 | 795 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2012 | 771 | 0.020 |
Why?
| | Cell Movement | 1 | 2012 | 967 | 0.020 |
Why?
| | Brain | 1 | 2020 | 2668 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 916 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1692 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 1774 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2010 | 1178 | 0.020 |
Why?
| | Fibroblasts | 1 | 2010 | 996 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3196 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5079 | 0.010 |
Why?
|
|
Balakrishnan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|